Valuation: Carmat SA

Market Cap 6.15M 7.12M 5.78M 5.25M 9.87M 680M 10.04M 67.67M 26.46M 341M 26.72M 26.14M 1.13B P/E 2023
-3.09x
P/E 2024 -0.95x
Enterprise Value 59.25M 68.6M 55.67M 50.63M 95.19M 6.56B 96.76M 652M 255M 3.28B 258M 252M 10.92B EV / Sales 2023
56.1x
EV / Sales 2024 13.5x
Free-Float
89.06%
Yield 2023 *
-
Yield 2024 -
Current year 0.1
Extreme 0.099
0.1
1 year 0.08
Extreme 0.085
0.47
3 years 0.08
Extreme 0.085
9.99
5 years 0.08
Extreme 0.085
31.7
10 years 0.08
Extreme 0.085
44.95
Manager TitleAgeSince
Chief Executive Officer 55 2016-08-31
Director of Finance/CFO - 2018-12-11
Chief Tech/Sci/R&D Officer - 2025-03-31
Director TitleAgeSince
Director/Board Member 55 -
Director/Board Member 68 2017-01-01
Director/Board Member 79 2017-04-19
Date Insider Type Main position Quantity % Market Cap.
3/13/25 Sell

Chairman

1,343,333 2.3347%
3/13/25 Buy

Chairman

1,343,333 2.3347%
5/29/24 Buy

Director

1,343,333 4.6122%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-78.94%-98.65% 7.08M
-0.55%+0.05%-10.39%+19.11% 130B
-0.86%-1.53%-18.99%-0.90% 12.49B
-2.60%+2.51%+102.60%+150.01% 10.88B
-2.43%-4.22%-44.77%-67.94% 4.51B
-0.88%+0.67%-21.71%+44.12% 2.72B
-1.32%-1.42%-19.74%-14.08% 1.66B
-1.89%-5.09%-32.49%-77.29% 1.65B
-0.17%-0.04%-31.76%-35.90% 1.66B
Average -1.19%-0.70%-17.35%-9.06% 18.41B
Weighted average by Cap. -0.78%-0.05%-5.27%+22.39%

Financials

2023 2024
Net sales 3.84M 4.44M 3.61M 3.28M 6.16M 425M 6.27M 42.25M 16.52M 213M 16.68M 16.32M 707M 7.34M 8.5M 6.9M 6.28M 11.8M 813M 11.99M 80.86M 31.62M 407M 31.92M 31.23M 1.35B
Net income -53.87M -62.37M -50.62M -46.04M -86.55M -5.96B -87.98M -593M -232M -2.99B -234M -229M -9.92B -51.4M -59.51M -48.3M -43.92M -82.58M -5.69B -83.94M -566M -221M -2.85B -223M -219M -9.47B
Net Debt 49.64M 57.47M 46.64M 42.42M 79.75M 5.5B 81.07M 547M 214M 2.75B 216M 211M 9.14B 53.1M 61.48M 49.9M 45.38M 85.32M 5.88B 86.72M 585M 229M 2.94B 231M 226M 9.78B
Logo Carmat SA
Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Employees
153
  1. Stock Market
  2. Stocks
  3. ALCAR Stock